You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
2021-10-04
Oct 4, 2021
C
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Recruiting
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Lymphoma, Non-Hodgkin
  • New York, New York
  • +13 more
2021-08-26
Aug 26, 2021
D
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Active, not recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Duarte, California
  • +5 more
2022-03-28
Mar 28, 2022
T
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
2021-09-29
Sep 29, 2021
I
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Recruiting
  • Non Hodgkins Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Aichi, Japan
  • +4 more
2022-01-24
Jan 24, 2022
H
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Recruiting
  • B-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Birmingham, Alabama
  • +27 more
2022-03-30
Mar 30, 2022
K
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL
Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Louisville, Kentucky
    Norton Cancer Institute
2022-03-01
Mar 1, 2022
O
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Active, not recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
  • Yamagata, Japan
    Yamagata University Hospital
2022-02-21
Feb 21, 2022
S
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Recruiting
  • DLBCL
  • R-DHAP
  • Brentuximab Vedotin
  • Rotterdam, Netherlands
    NL-Rotterdam-ERASMUSMC
2020-12-09
Dec 9, 2020
T
Study of Lacutamab in Peripheral T-cell Lymphoma
Recruiting
  • Peripheral T Cell Lymphoma
  • Relapse/Recurrence
  • Antwerpen, Belgium
  • +38 more
2021-12-06
Dec 6, 2021
A
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Not yet recruiting
  • Non-Hodgkin Lymphoma
  • New Haven, Connecticut
  • +76 more
2022-03-09
Mar 9, 2022
H
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Active, not recruiting
  • B-cell Non-Hodgkin Lymphoma
  • Birmingham, Alabama
  • +40 more
2022-03-17
Mar 17, 2022
S
Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL - 2021
Completed
  • Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
    • Seoul, Gangnam-Gu, Korea, Republic of
      Samsung Medical Center
    2022-02-04
    Feb 4, 2022
    M
    MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
    Recruiting
    • Acute Lymphoblastic Leukemia Recurrent
    • +4 more
    • MB-CART19.1
    • Berlin, Germany
    • +9 more
    2021-11-30
    Nov 30, 2021
    A
    AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
    Recruiting
    • Relapsed/Refractory Peripheral T-cell Lymphoma
    • Relapsed/Refractory Classical Hodgkins Lymphoma
    • Duarte, California
    • +27 more
    2022-03-01
    Mar 1, 2022
    H
    Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
    Active, not recruiting
    • Peripheral T-Cell Lymphoma (PTCL)
    • Akita, Japan
    • +22 more
    2021-12-09
    Dec 9, 2021
    N
    Study of Out of Specification for Tisagenlecleucel
    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • Diffuse Large B-cell Lymphoma
    • Tisagenlecleucel
    • Hamilton, Ontario, Canada
    • +33 more
    2022-01-28
    Jan 28, 2022
    U
    Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
    Recruiting
    • Acute Lymphoblastic Leukemia, Adult
    • +5 more
    • CD19.CAR T Cells
    • +2 more
    • Heidelberg, Germany
    • +1 more
    2020-11-18
    Nov 18, 2020
    P
    Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
    Recruiting
    • Non-Hodgkin's Lymphoma, Relapsed
    • +8 more
    • PBCAR20A
    • +2 more
    • Duarte, California
    • +4 more
    2021-04-28
    Apr 28, 2021
    S
    DLBCL Treatment in Children and Adolescents - 2020
    Completed
    • Diffuse Large B-cell Lymphoma
    • CHOP and BFM regiments
    • (no location specified)
    2021-01-25
    Jan 25, 2021
    N
    Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
    Active, not recruiting
    • Non-Hodgkin Lymphoma
    • Tisagenlecleucel
    • Los Angeles, California
    • +25 more
    2022-03-04
    Mar 4, 2022
    H
    A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
    Recruiting
    • B-cell Non-Hodgkin Lymphoma
    • Mosunetuzumab (IV)
    • +3 more
    • Birmingham, Alabama
    • +20 more
    2022-03-17
    Mar 17, 2022
    H
    A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Birmingham, Alabama
    • +73 more
    2022-04-05
    Apr 5, 2022
    B
    A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
    Active, not recruiting
    • Hematoma
    • Beijing, China
      Beijing university cancer hospital
    2022-01-10
    Jan 10, 2022
    C
    A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Recruiting
    • Lymphoma, Non-Hodgkin
    • Minneapolis, Minnesota
    • +11 more
    2022-02-10
    Feb 10, 2022